The war against the chikungunya virus that claims lives, which is dominant along the country's coastal towns, has suffered a setback after the U.S.
Food and Drug Administration (FDA) suspended the license for its vaccine, Ixchiq, with immediate effect.
A French pharmaceutical company that manufactures the vaccine, confirmed that the suspension followed reports of four serious adverse events consistent with the disease.
As a result, the company has been ordered to stop shipping and selling the vaccine in the U.S.
